Literature DB >> 19058216

Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.

Dejana Braithwaite1, C Martin Tammemagi, Dan H Moore, Elissa M Ozanne, Robert A Hiatt, Jeff Belkora, Dee W West, William A Satariano, Michael Liebman, Laura Esserman.   

Abstract

The objective of this study was to determine whether comorbidity, or pre-existing conditions, can account for some of the disparity in survival between African-American and white breast cancer patients. A historical cohort study was conducted of 416 African-American and 838 white women diagnosed with breast cancer between 1973 and 1986, and followed through 1999 in the Kaiser Permanente Northern California Medical Care Program. Information on comorbidity, tumor characteristics and breast cancer treatment was obtained from medical records, and Surveillance, Epidemiology and End Results, Northern California Cancer Center Registry. Associations between comorbidity and survival were analyzed with multiple Cox proportional hazards regression. Over a mean follow-up of 9 years, African Americans had higher overall crude mortality than whites: 165 (39.7%) versus 279 (33.3%), respectively. When age, race, tumor characteristics and breast cancer treatment were controlled, the presence of hypertension was associated with all cause survival [hazard ratio (HR) = 1.33, 95% confidence intervals (CI) 1.07-1.67] and it accounted for 30% of racial disparity in this outcome. Hypertension-augmented Charlson Comorbidity Index was a significant predictor of survival from all causes (HR = 1.32, 95%CI 1.18-1.49), competing causes (HR = 1.52, 95%CI 1.32-1.76) and breast cancer specific causes (HR = 1.18, 95%CI 1.03-1.35). In conclusion, hypertension has prognostic significance in relation to survival disparity between African-American and white breast cancer patients. If our findings are replicated in contemporary cohorts, it may be necessary to include hypertension in the Charlson Comorbidity Index and other comorbidity measures.

Entities:  

Mesh:

Year:  2009        PMID: 19058216     DOI: 10.1002/ijc.24054

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  53 in total

1.  Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors.

Authors:  Minjee Lee; Ramzi G Salloum
Journal:  J Cancer Surviv       Date:  2015-11-30       Impact factor: 4.442

2.  Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation.

Authors:  Joseph M Unger; Dawn L Hershman; Mark E Fleury; Riha Vaidya
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

3.  Breast cancer molecular subtypes of Uygur and Han in Xinjiang of China.

Authors:  Cheng-Hui Wang; Jun-Zhi Li; Wei Zhang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  The Effects of Social and Behavioral Determinants of Health on the Relationship Between Race and Health Status in U.S. Breast Cancer Survivors.

Authors:  Yao Yuan; Monica Taneja; Avonne E Connor
Journal:  J Womens Health (Larchmt)       Date:  2018-12-19       Impact factor: 2.681

5.  Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy.

Authors:  Michela Dispinzieri; Eliana La Rocca; Elisabetta Meneghini; Alba Fiorentino; Laura Lozza; Serena Di Cosimo; Massimiliano Gennaro; Vito Cosentino; Milena Sant; Emanuele Pignoli; Riccardo Valdagni; Francesca Bonfantini; Maria Carmen De Santis
Journal:  Med Oncol       Date:  2018-06-16       Impact factor: 3.064

6.  Physical activity in Black breast cancer survivors: implications for quality of life and mood at baseline and 6-month follow-up.

Authors:  Allyson D Diggins; Lauren E Hearn; Suzanne C Lechner; Debra Annane; Michael H Antoni; Nicole Ennis Whitehead
Journal:  Psychooncology       Date:  2016-02-28       Impact factor: 3.894

7.  The Detroit Research on Cancer Survivors (ROCS) Pilot Study: A Focus on Outcomes after Cancer in a Racially Diverse Patient Population.

Authors:  Jennifer L Beebe-Dimmer; Terrance L Albrecht; Tara E Baird; Julie J Ruterbusch; Theresa Hastert; Felicity W K Harper; Michael S Simon; Judith Abrams; Kendra L Schwartz; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-27       Impact factor: 4.254

8.  Medical comorbidities predict mortality in women with a history of early stage breast cancer.

Authors:  Ruth E Patterson; Shirley W Flatt; Nazmus Saquib; Cheryl L Rock; Bette J Caan; Barbara A Parker; Gail A Laughlin; Kirsten Erickson; Cynthia A Thomson; Wayne A Bardwell; Richard A Hajek; John P Pierce
Journal:  Breast Cancer Res Treat       Date:  2010-01-14       Impact factor: 4.872

9.  The prevention of cardiovascular disease in cancer survivors.

Authors:  Iyad N Daher; Tina R Daigle; Nirmanmoh Bhatia; Jean-Bernard Durand
Journal:  Tex Heart Inst J       Date:  2012

10.  The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival.

Authors:  Anna H Wu; Scarlett Lin Gomez; Cheryl Vigen; Marilyn L Kwan; Theresa H M Keegan; Yani Lu; Salma Shariff-Marco; Kristine R Monroe; Allison W Kurian; Iona Cheng; Bette J Caan; Valerie S Lee; Janise M Roh; Jane Sullivan-Halley; Brian E Henderson; Leslie Bernstein; Esther M John; Richard Sposto
Journal:  Cancer Causes Control       Date:  2013-07-18       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.